TTP Introduces Cellular Origins, a TTP Company Focussed on Delivering Scalable Manufacture of Cell and Gene Therapies
TTP, a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary technology addresses the current barriers associated with the manufacture of advanced therapies that are in late-stage development, enabling commercial manufacturing without process change. By providing a solution for automated sterile fluidic interconnection that has the flexibility to adapt and link current and future bioprocess equipment, Cellular Origins enables full automation of current cell therapy manufacturing and future innovation of new processes.
The cell and gene therapy market has seen dramatic growth over recent years, with a predicted 64 new cell and gene therapies approved, and a total market value of >$90bn (CAGR 22%) by 20301,2. Over the same period, manufacturers have struggled to meet demand for cost-effective, scalable therapy manufacture. There is therefore an urgent and growing need for manufacturing solutions that provide large-scale access to cost-effective, next-generation therapeutics. Cellular Origins has been formed to meet this specific need.
Cellular Origins, harnessing an expert team from across the life science, robotics and engineering industries, and backed by TTP, is developing a proprietary automation platform to meet the needs of advanced therapy manufacture. The Company’s proprietary technology has been developed as a transformative solution for automated, sterile, fluidic end-to-end interconnection throughout the manufacture workflow. The platform has been developed for ultimate flexibility, with the ability to integrate current workflows and existing instrumentation with future process innovation. By addressing these core constraints to advanced therapy manufacturing, Cellular Origins is focussed on enabling developers to get their therapies to market, enabling patient access to the very latest cell and gene therapies.
Matthew Carr, Head of Life Sciences, TTP plc, said: “We are really excited to announce the launch of Cellular Origins. For over 30 years, TTP has worked with some of the world’s most innovative and ambitious biotech companies, developing new tools and technologies. We have also built companies in the life science space such as TAP Biosystems, TTP Labtech and more latterly, Cellular Highways (www.cellularhighways.com). We have every confidence that Cellular Origins will deliver on its mission to address the urgent need for scalable, cost-effective and efficient manufacture of cell and gene therapies, enabling many more patients to benefit from the very latest advances in cell therapy.”
Dr Edwin Stone, CEO of Cellular Origins, commented: “We are extremely pleased to officially announce the launch of Cellular Origins. Cell and gene therapies are creating a therapeutic revolution that will change lives, but without a revolution in manufacturing, patients will not be able to access these therapies. Our team comprises experts in life science, robotics and engineering, with a proven track record from creating the first highly scaled out roller bottle manufacturing platform for Amgen to developing over 10 separate cell and gene therapy automation projects. Cellular Origins’ goal is to offer customers access to large-scale, efficient, and affordable production of next-generation therapies, but also to do so without limiting manufacturer’s choice of instrumentation, or requiring changes to existing workflows.”
- OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Read more
- Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer Read more
- BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Read more
- Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read more
- Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Read more